Back to News
Market Impact: 0.3
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
Source: benzinga.com
Corporate EarningsCompany FundamentalsCorporate Guidance & Outlook
VolitionRx shares are surging after reporting 112% YoY revenue growth in 1H 2026 to $1.4M, driven by expanded clinical and commercial operations. The company’s top-line acceleration suggests improving business momentum, which is likely to be a near-term positive catalyst for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
VNRX0.60
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations
- Selecting an AI Research Platform for Institutional Investors